- Home
- MMA vs TPST Comparison
MMA vs TPST Comparison
Compare MMA & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MMA | TPST |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9M | 15.6M |
| IPO Year | 2023 | 2012 |
Fundamental Metrics
Financial Performance| Metric | MMA | TPST |
|---|---|---|
| Price | $0.48 | $1.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | ★ 14.4M | 245.8K |
| Earning Date | 05-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.35 | $0.84 |
| 52 Week High | $2.00 | $12.22 |
Technical Indicators
Market Signals| Indicator | MMA | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 55.72 | 52.69 |
| Support Level | $0.45 | $1.02 |
| Resistance Level | $0.58 | $1.09 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 19.32 | 52.95 |
Price Performance
Historical ComparisonAbout MMA Alta Global Group Limited
MMA Inc develops technology solutions for the martial arts and combat sports sector. Its platform is designed to support gyms and related businesses by improving areas such as sales channels, customer onboarding, and member engagement. The platform also connects participants, gyms, and communities within the sector, enabling digital management and interaction.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.